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Abstract: MALDI imaging mass spectrometry (MALDI-IMS) allows acquisition of mass 
data  for  metabolites,  lipids,  peptides  and  proteins  directly  from  tissue  sections.  IMS  is 
typically performed either as a multiple spot profiling experiment to generate tissue specific 
mass profiles, or a high resolution imaging experiment where relative spatial abundance for 
potentially  hundreds  of  analytes  across  virtually  any  tissue  section  can  be  measured. 
Crucially,  imaging  can  be  achieved  without  prior  knowledge  of  tissue  composition  and 
without the use of antibodies. In effect MALDI-IMS allows generation of molecular data 
which  complement  and  expand  upon  the  information  provided  by  histology  including 
immuno-histochemistry, making its application valuable to both cancer biomarker research 
and diagnostics. The current state of MALDI-IMS, key biological applications to ovarian 
cancer research and practical considerations for analysis of peptides and proteins on ovarian 
tissue are presented in this review. 
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1. Epidemiology of Ovarian Cancer 
In  2010, an estimated  21 880 new cases of ovarian cancer  will  be diagnosed in the USA  [1]. 
http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-and-figures-2010. 
With a projected 13 850 deaths from this disease in 2010, ovarian cancer has the highest mortality 
rate of all gynaecological malignancies. The high mortality from ovarian cancer is due to the majority 
of patients (64%, see Table 1) being diagnosed with advanced (International Federation of Gynecology 
and Obstetrics (FIGO) stage III + IV) disease, which has a maximum 5-year survival of only 30% [2]. 
In contrast, the 5-year survival for patients with organ-confined FIGO stage I ovarian cancer exceeds 
90% and a large number of these patients are cured. Thus, early detection is the key to increased 
survival in ovarian cancer. 
Table 1. FIGO ovarian cancer stages, prevalences and anatomical features. 
FIGO Stage  Prevalence (%)  Anatomical features 
I  25  Limited to ovaries 
II  11  Pelvic extension 
III  47  Abdominal extension and/or positive lymph nodes 
IV  17  Distant metastases 
2. Early Detection of Ovarian Cancer 
While other gynaecological cancers can be diagnosed at an early stage due to effective screening 
(e.g., PAP smear in the case of cervical cancer) or symptoms (e.g., bleeding in the case of endometrial 
cancer), neither specific early disease symptoms or an early detection test exist for ovarian cancer. 
Presently,  diagnosis  involves  a  combination  of  physical  examination,  followed  by  trans-vaginal 
ultrasound, measurement of serum levels of the glycoprotein CA-125 and exploratory surgery if a 
suspicious ovarian lesion has been identified  [1]. CA-125, when combined with ultrasound, has a 
positive predictive value (PPV) of only 35.1% for primary EOCs [2]. This low PPV indicates that two 
out of every three patients will be over diagnosed and undergo unnecessary and potentially harmful 
invasive procedures. Novel biomarkers are therefore required to improve ovarian cancer detection. 
Single markers, such as CA125, are unlikely to provide the sensitivity and specificity required for 
ovarian cancer screening [3]. The focus has thus shifted to panels of biomarkers, which for the moment 
are  additional  diagnostic  tools,  not  screening  options  [4,5].  Further  improvements  to  these  panels 
require not only discovery of new biomarkers, but also validation of existing biomarker candidates. 
Moreover, the large numbers of newly identified potential biomarkers have to be validated individually 
in a large cohort of patients, which is currently impractical. The use of serum or plasma for many 
biomarker discovery projects also complicates the process of biomarker discovery, as serum has a high 
protein complexity, large dynamic range of protein concentration (10
12) [6] and contains non-specific 
acute phase proteins. A more promising approach is therefore the direct analysis of the cancer tissue, 
as it should have the highest concentration of disease specific markers [7] and a smaller dynamic range 
of  protein  concentration  (10
6)  [8].  Thus,  by  focusing  on  tissue  identified  candidates  it  should  be 
possible to compile a smaller subset of biomarkers with a higher specificity which can be validated in 
situ by immuno-histochemistry (IHC) and subsequently in large patient cohorts by established methods Int. J. Mol. Sci. 2011, 12                       
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like enzyme linked immuno-sorbent assays (ELISA). These biomarkers could then be used in novel 
high specificity panels for early diagnosis of ovarian cancer. 
3. Molecular Classification of Ovarian Carcinomas 
The absence of reliable biomarkers is not the only issue with respect to ovarian cancer diagnosis. 
Following  histologic  confirmation  of  ovarian  disease,  treatment  is  assigned  based  upon  stage  [1]. 
Ovarian  cancer  staging  is  currently  defined  by  the  FIGO  classification  system  for  tumour 
dissemination  into  extra-ovarian  sites  (see  Table  1),  which  correlates  well  with  patient  five  year 
survival  (see  SEER  http://seer.cancer.gov/statfacts/html/ovary.html)[9,10].  However,  grade  is  an 
additional important prognostic parameter [11]. Grade, as determined by light microscopy describes 
morphological  characteristics  of  tumour  tissue  including  percentage  of  solid  growth,  architecture, 
nuclear features and mitotic activity (see Table 2). [12]. These characteristics are subjective and their 
reproducibility may be suboptimal [12]. Moreover, contention exists as to which grading systems most 
accurately reflect ovarian tumour differentiation status and therefore optimal treatment [12,13].  
Table  2.  Grading  systems  for  epithelial  ovarian  carcinoma:  FIGO,  universal  three  tier 
grading and two tier grading. 
Grading system  Grade  Key features  Ref. 
FIGO 
1  Well differentiated  Grade based on % 
solid non-squamous 
growth, grade + 1 if 
nuclear atypia apparent 
<5% solid growth 
[10] 
2 
Moderately 
differentiated 
6–50% solid growth 
3  Poorly differentiated  >50% solid growth 
[13] 
3-tier universal 
grading 
1 
Grade based on sum 
of individual feature 
scores (see right)  
1 = 3–5 points  
2 = 6–7 points  
3 = 8–9 points 
Architecture based 
score 
Glandular = 1 point 
Papillary = 2 points 
Solid = 3 points 
2 
Nuclear pleomorphism 
score 
Slight = 1 point    
Moderate = 2 points 
Marked = 3 points 
[12] 
3  Mitotic activity score 
0–9 = 1 point                    
10–24 = 2 points             
≥25 = 3 points  
2-tier 
grading 
Serous 
tumour 
Low grade 
(type I) 
Slow development 
Low chromosomal 
instability 
Gene mutation–
KRAS, BRAF, ERBB2 
[14] 
High grade 
(type II) 
Rapid development 
High chromosomal 
instability 
Gene mutation–P53 
Endomet
roid 
tumour 
Low grade 
Well differentiated, 
no necrosis 
Solid glandular 
architecture 
Gene mutation–Wnt, 
PI3K/Akt 
[13] 
High grade 
Solid growth >50%, 
necrosis 
Diffusely infiltrative 
or expansive growth, 
no glandular 
architecture 
Gene mutation–TP53  [16] 
 
Based on recent advances in the understanding of the molecular biology of ovarian cancer it is now 
believed that the major ovarian cancer subtypes can be separated (see Table 2) into type I (low grade) 
or  type  II  (high  grade)  based  upon  differential  gene  and/or  protein  expression  [13–16].  These  Int. J. Mol. Sci. 2011, 12                       
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two-tiered  molecular  systems  of  ovarian  cancer  grading  provide  an  avenue  for  defining  cancer 
differentiation state in absolute terms. As such, molecular grading systems need to be developed to a 
point where they can complement routine histo-pathological examination of ovarian cancer tissue. 
Importantly, this also needs to be achieved on a similar time scale to histology, in this case one to  
two hours. 
Thus, to improve EOC management and outcome for patients, both discovery of novel, effective 
biomarkers and development of a new molecular grading/classification system are required. 
4. Application of Proteomics to Ovarian Cancer 
Although gene expression is useful for distinguishing ovarian tumour subtypes [14], it does not 
always  correlate  with  protein  translation  [17,18],  nor  can  levels  of  post  translational  modification 
(PTM) be directly inferred from genetic analyses [19]. However, both protein expression level and 
PTM state have drastic effects on cellular function/dysfunction and as a result it is more meaningful to 
analyse the disease-related proteins and peptides. Generating protein profiles with sufficient molecular 
features is impossible with IHC, as it is limited to a maximum of three to four antibodies at a time and, 
crucially, depends on antibody quality. Proteomics, however, allows analysis of hundreds to thousands 
of  peptide  and  protein  features  in  biological  samples  [20],  in  many  cases  without  the  need  
for antibodies.  
The term ―proteomics‖ was coined to describe the quantitative analysis of the proteome, which 
represents all proteins expressed in a given cell, tissue (e.g., cancer) or biological fluid (e.g., serum) at 
a  given  point  in  time  or  under  the  effects  of  a  defined  biological  stimulus  [21].  High  analytical 
sensitivity  is  achieved  in  proteomics  because  complex  protein  mixtures  are  fractionated  following 
tissue or cell lysis (disruption), followed by further purification or direct analysis by mass spectrometry 
(MS) [22,23]. These methods allow for identification of thousands of proteins from a single cell lysate. 
For example, two separate studies from 2006 [24] and 2008 [19] demonstrated profiling of ovarian 
cancer subtypes using liquid chromatography (LC) separation followed by MS (LC-MS). The 2008 
study  showed  that  early  and  late  stage  endometroid  ovarian  carcinoma  MS  profiles  can  be 
distinguished using a clustering analysis, which separates profiles based on feature similarity; in this 
case similar protein masses [19]. Importantly, the 2008 publication also combined profiling MS data 
for serous and clear cell tumours from the 2006 study [24] to show that the three subtypes grouped 
separately in a principal component analysis (PCA). These studies are significant as they indicate that 
―classical‖ proteomics can generate molecular fingerprints of disease. However, there are two issues 
for implementing proteomics in this manner. Firstly, tissue disruption for analysis removes spatial 
proteome information, which is critical for clinical application, especially in heterogeneous carcinomas 
where different structural elements will express a unique proteome with subsequent unique cellular 
function. A common method for addressing this problem is laser capture micro-dissection (LCM) [7], 
which can isolate specific cell populations for analysis. However, similar to many proteomics methods, 
including liquid phase separation, LCM is time consuming. The second issue is thus that a proteomic 
method is required that can be implemented in the same time frame as classical histology (i.e., one to 
two hours). 
   Int. J. Mol. Sci. 2011, 12                       
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5. Tissue Analysis by Mass Spectrometry 
Direct tissue section analysis utilising an MS instrument removes the need for disruption and the 
subsequent loss of spatial proteome information. This approach also provides an avenue for molecular 
classification/grading because tissue sections can be prepared and analysed rapidly (1–3 hours) using 
standardised  protocols.  Importantly,  tissue  specific  biomarkers  can  be  visualised  and  subsequently 
identified using ―classical‖ proteomics methods such as LC-MS. For easy reference, the advantages 
and disadvantages of methods for analysing tissues (histology, IHC and proteomics) are summarised in 
Table 3.  
Table 3. Comparison of different methods (histology, immuno-histochemistry (IHC) and 
proteomics (fractionation coupled to mass spectrometry (MS) and direct tissue MS) for 
peptide/protein analysis in tissue samples. 
  Histology  IHC 
Proteomics 
Fractionation-MS  Direct tissue MS 
Methods  Cellular staining 
Antibody directed 
staining of specific 
proteins 
Liquid phase separation 
(i.e., liquid 
chromatography) 
Direct measurement of 
peptides and proteins from 
tissue section 
Analysis 
Tissue morphology 
assessment by light 
microscopy 
Protein distribution 
across tissue 
sections 
MS protein 
identification 
MS profiles of tissue 
sections 
Quantitation using 
protein labelling 
Peptide and protein intensity 
maps showing distribution 
across tissue sections 
Advantages 
Easy staining 
methods 
Highly specific  Highly sensitive  Rapid 
Cellular microscopy 
resolution 
Cellular microscopy 
resolution 
Thousands of proteins 
analysed at a time 
Spatial proteome 
information 
Well established  Well established  Heavily automated 
Measurement of hundreds of 
molecular features at a time 
Clinical personnel 
already available 
Clinical personnel 
already available 
Highly modular 
workflows 
No antibodies required 
Disadvantages 
Reproducibility 
issues 
Time consuming  Time consuming  Expensive equipment 
Based on visual 
assessment of 
morphology 
Labor intensive  Labor intensive  Novel technology 
Non-specific 
Limited to 3–4 
proteins 
Removes spatial 
information 
Requires fraction-MS based 
proteomics to identify 
peptide and protein features 
Analysis is 
subjective 
Dependent on 
antibody quality 
Requires specialist 
personnel 
Analytical resolution limited 
to a maximum of 20–50 µ m 
 
MS  measurement  of  molecules  directly  from  tissue  was  first  described  in  1997  [25].  MS 
instruments measure the mass to charge ratio (m/z) of gaseous ions, in this case peptide or protein ions. 
Mass is of value because it indicates composition, which, for example, can be used to identify proteins Int. J. Mol. Sci. 2011, 12                       
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of interest by their component peptides. To generate ions directly from tissue, either secondary ion MS 
(SIMS) or matrix-assisted laser desorption/ionisation (MALDI) instruments are utilised.  
SIMS utilises the impact of an ion beam (e.g., Ar
+ or Ga
+) to induce a localised gain in kinetic 
energy on the tissue surface. Once a sufficient energy level is reached secondary ions (e.g., peptides) 
are ejected from the tissue for mass measurement [26]. In practice, SIMS causes surface fragmentation 
and as a result limits measurement to metabolites, lipids and small peptides (<1000 Da) [26]. 
MALDI represents a more suitable ionisation method for direct application to tissue. Preparation for 
MALDI requires a tissue section to be coated with a low molecular weight organic molecule, called the 
―matrix‖.  The  most  common  matrix  compounds,  2,5-dihydroxybenoic  acid  (DHB),  
α-cyano-4-hydroxycinnamic acid (CHCA), and sinapinic acid (SA) are listed in Table 4 along with 
example modifications made to the matrix composition, their full chemical names and bio-molecule 
specificity.  Several  of  these  matrix  combinations  have  been  applied  to  ovarian  tissue  including  
DHB/3-AP [27], CHCA [28], CHCA/ANI [28], SA [28,29], SA/3-AP [30] and SA/HFIP [30,31]. Most 
matrixes are dissolved in a 50–60% acidified organic solvent solution, which extracts lipids, peptides 
and proteins from the tissue prior to evaporation, allowing the matrix to crystallise. The end result is a 
field of sample-matrix co-crystals on the tissue surface. 
Table 4. List of the three most common matrix types―2,5-dihydroxybenzoic acid (DHB), 
α-cyano-4-hydroxycinnamic  acid  (CHCA)  and  3,5-dimethoxy-4-hydroxycinnamic  acid 
(sinapinic  acid,  SA)  as  well  as  their  documented  modifications  -  for  MALDI  mass 
spectrometry. Suitability for measurement of bio-molecules is specified [26]. 
Matrix  Chemical name  Biomolecule specificity 
DHB  2,5-dihydroxybenzoic acid  Lipids, peptides, <10 kDa proteins 
DHB/aniline  DHB + aniline  Lipids, peptides, <10 kDa proteins 
DHB/3-AP  DHB + 3-acetyl pyridine  Lipids, peptides, <10 kDa proteins 
CHCA  α-cyano-4-hydroxycinnamic acid  Peptides, small proteins (<10 kDa) 
CHCA/aniline  CHCA + aniline  Peptides, <10 kDa proteins 
SA  3,5-dimethoxy-4-hydroxycinnamic acid  Proteins (>10 kDa) 
SA/aniline  SA + aniline  Proteins (>10 kDa) 
SA/3-AP  SA + 3-acetyl pyridine  Proteins (>10 kDa) 
SA/HFIP  SA + 1,1,1,3,3,3-hexafluoro-2-propanol  Proteins (>30 kDa) 
SA/TFE  SA + 2,2,2-trifluoroethanol  Proteins (>30 kDa) 
MALDI is achieved by directing a laser beam at the co -crystals. The matrix absorbs the bulk of 
incident laser energy, causing an explosive transition from solid crystal to a gaseous plume, during 
which ionisation of the sample occurs (see Figure 1)  [32–35].  MALDI  is  suited  to  bio-molecule 
analysis because it is a ―soft” ionisation process, in that the matrix is the energy absorber, minimising 
protein/peptide fragmentation. MALDI ion sources are typically coupled to time-of-flight (TOF) mass 
analysers. Ions from the MALDI process are accelerated into the TOF tube, which is an electric field 
free flight region. The kinetic energy gained during acceleration decreases with increasing mass and as 
such heavier ions will fly slower and therefore have a longer time-of-flight. This is the basis of TOF 
mass analysis. When an ion hits an attached detector, the time from laser ionisation to detection is used 
to derive m/z (see Figure 1). The end result is a plot of m/z against intensity (ion counts); commonly Int. J. Mol. Sci. 2011, 12                       
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referred to as an MS spectrum. The preference of most groups for MALDI-TOF instruments is due to 
their sensitivity (femto to attomolar range under ideal conditions), ease of use and achievable mass 
range of MALDI-TOF, which reaches from small molecules (100 Da) to large proteins (>300 kDa), 
allowing measurement of metabolites, lipids, peptides and proteins on the same instrument. 
Figure 1. Basic principles of matrix-assisted laser desorption/ionisation (MALDI) time-of-
flight (TOF) mass spectrometry. Following ionisation, sample ions are accelerated into an 
electric field free ―drift‖ region. The larger the ion the less energy it will gain during 
acceleration and as a result it will travel slower than smaller ions. This is the basis of time 
of flight separation. Time from laser ionisation to detection at the opposite end of the drift 
region is used to determine mass to charge ratio (m/z) for masses between 0–300 kDa. 
High mass accuracy is achieved using a reflector field that focuses ions from 0–6 kDa onto 
a secondary detector. 
 
The key advantages of MALDI-TOF MS application directly to tissue are thus that: 
(i)  Several bio-molecule classes from different mass ranges can be  measured, including drugs 
[36], lipids [27], peptides [37,38] and proteins [31,39,40].  
(ii)  Several hundred molecular features can be measured in a single experiment (see Figure 3a–c). 
(iii) No preliminary knowledge about tissue composition is required. 
(iv) No antibodies are required. 
6. Methods for in Situ MALDI-TOF Analysis of Ovarian Cancer Tissue 
An outline of the methodology for in situ MS analysis of ovarian tissue is shown in Figure 2. 
Sectioned tissue (2–10 µm thick) is mounted directly onto chilled conductive glass slides (indium tin 
oxide coated) or metallic targets (e.g., gold coated target). The mounted sections are dried (15–45 min) 
before  fixation  with  a  graded  alcohol  series  (70%  and  100%  v/v  ethanol/isopropanol)  or  organic 
solvents such as chloroform or acetone [41–44]. This fixation has been shown to increase the quality of 
MS signals, most likely as a result of physiological salt and lipid removal, both of which interfere with 
matrix crystallisation and subsequent quality of MS data [42,43]. For ovarian tissue, washes with 70% Int. J. Mol. Sci. 2011, 12                       
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and 100% isopropanol are sufficient to generate rich small protein (Figure 3a) and endogenous peptide 
(Figure 3b) MS signals directly from carcinoma sections. However, chloroform can also be used quite 
successfully as a stand-alone wash prior to analysis [30]. As described previously, to allow MALDI 
measurement, the tissue is coated with a matrix solution. The method of matrix coating is important as 
it affects the type (single spectra or multiple) and quality (MS sensitivity) of data obtained. These 
methods are discussed further as they pertain to the two types of in situ MALDI-TOF MS experiment, 
profiling and imaging MS (IMS). 
Figure 2. The top panel shows a typical workflow for IMS on ovarian tissue. Note the 
optional tryptic digest (absolute requirement for formalin-fixed paraffin embedded (FFPE) 
tissue). Antigen retrieval can also be used to partially hydrolyse formalin-induced protein 
cross-links.  The  bottom  panel  shows  the  two  analysis  workflows  possible  for  an  IMS 
experiment, profiling and imaging. 
 
   Int. J. Mol. Sci. 2011, 12                       
 
 
781 
Figure 3. Data from printed arrays on stage IIIC ovarian epithelial carcinoma. The spectra 
in a-d represent the sum of all spectra for small protein (a–matrix only + peptide/ small 
protein mass range), endogenous peptide (b–matrix only + peptide mass range) and tryptic 
peptide  (c–trypsin  digestion  +  matrix  with  peptide  mass  range)  analysis  using  a  
MALDI-TOF/TOF  MS  instrument.  Twenty  mg/mL  DHB  in  50%  methanol  and  0.2% 
trifluoroacetic  acid  was  used  as  a  matrix.  Trypsin  was  used  at  40  ng/µ L  in  a  5  mM 
NH4HCO3 and 12% acetonitrile buffer at pH ~8.5. Panel d shows two morphologically 
different  areas  on  a  H&E  stained  section  (green/red  outlines),  previously  analysed  by 
tryptic peptide IMS. Three ion intensity maps with associated spectra for the green and red 
areas show differential peptide distribution. 
 Int. J. Mol. Sci. 2011, 12                       
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7. Profiling Cancer Tissues Using MALDI-TOF MS 
Typically, in situ MS methods are split into two types of workflows, these being profiling MS or 
IMS (see Figure 2, bottom panel). The profiling MS approach uses manual or automated deposition of 
matrix at discrete locations on a tissue section. MS spectra are then acquired from these positions and 
compared.  If  tissue  MS  profiles  are  known  from  previous  analyses,  the  same  tissue  type  can  be 
identified in future studies based on this profile, a process similar to the MALDI Biotyper platform 
used for identification of micro-organisms [45]. Because of the novelty of IMS research, there are few 
publications  dealing  exclusively  with  ovarian  cancer.  However,  successful  examples  of  molecular 
classification/grading have been published for non-small cell lung cancer (NSCLC) [46] and soft tissue 
sarcomas (STS) [47]. In the lung cancer study, 100 nL of sinapinic acid (SA, see Table 4) matrix was 
manually spotted onto 42 NSCLC tumours (>70% tumour cellularity) and 8 normal lung sections. MS 
data was acquired in a m/z range of 2–25 kDa on a MALDI-TOF MS system and 82 peaks specific to 
the cancerous tissue were selected for development of a class prediction model. The training model 
generated was applied to a validation set of 32 tumour and 5 normal lung sections. Based on the MS 
data all 32 tumours of the validation set were classified correctly as tumour or normal. Moreover, 
segregation  of  these  mass  signals  based  on  tumour  subtype,  in  this  case  14  adenocarcinoma, 
15 squamous  cell  carcinoma  and  5  large  cell  carcinoma,  allowed  for  100%  separation  of 
adenocarcinomas and squamous cell as well as squamous and large cell tumours. Only one large cell 
tumour was mis-classified as adenocarcinoma in the study [46]. The STS study was able to distinguish 
low and high grade STS using MALDI IMS profiling. Drops of SA matrix (200 nL) were applied 
directly to areas showing cellular proliferation following MALDI-compatible cresyl violet staining 
[47,48]. It was determined that calgizzarin (S100 A11), calcyclin, macrophage inhibitory factor and 
calgranulin were potentially diagnostic for high grade STS, with key extracellular proteins such as 
myosin being down-regulated in both low and high grade tumours as compared to control muscle 
tissue. These findings were confirmed using IHC against sections of tumour and control tissue [47].  
In addition, pilot experiments have been published for grading follicular lymphoma [49], detection 
of pre-invasive bronchial lesions [50] and prostate cancer [51,52], classification of meningiomas [53], 
and generation of prognostic information for gliomas [54]. These pilot studies have shown the utility 
of characterising disease via direct MS tissue section analysis to gain diagnostic [47] and prognostic 
data [54]. 
The most comprehensive study to date analysing EOC [30] profiled tissue from 19 ovarian tumours 
(10 benign, 6 carcinoma and 3 borderline). Three mass ranges were examined, combining data from 
typical IMS peptide (CHCA matrix, see Table 4) and small protein (SA matrix) analysis with a novel 
method for extracting high molecular weight proteins using SA dissolved in 1,1,1,3,3,3-Hexafluoro-2-
propanol (HFIP). Using stage III and IV tumours, as compared to benign tissue, it was possible to 
profile masses matching those of cancerous marker proteins previously identified in EOC, including 
tetranectin (17.7 kDa) and urokinase plasminogen activator (36.9 kDa) [30]. Figure 4 highlights the 
differences between tissues as a plot of m/z against sample number as well as a PCA loadings plot 
showing separation of the benign, carcinoma and borderline tissues. Int. J. Mol. Sci. 2011, 12                       
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Figure 4. Figure from El Ayed et al. 2010 showing MALDI-TOF MS profiling on three 
classes of ovarian tissue (adenocarcinoma, borderline and benign). Plots of m/z against 
spectral source as well as loadings plots from principal component analysis are included 
for high mass proteins (A), small proteins (B) and peptides (C). Figure reprinted, with 
permission, from El Ayed et al. 2010 [30]. 
 
 
8. Profiling vs. Imaging 
Sample preparation for profiling involves deposition of larger (100–500 nL) drops of matrix onto 
discrete  positions  of  the  tissue  section.  In  contrast,  IMS  methods  require  nebulisation  of  a 
homogeneous layer of matrix or deposition of a rectangular array of smaller droplets (0.1–0.2 nL) onto 
tissue sections (Figure 2, bottom panel). The benefit of IMS is that instead of documenting profiles for 
singular locations, the relative abundance (based on MS signal intensity) of hundreds of protein or 
peptide ions is mapped across an entire tissue section at a centre to centre acquisition distance of 
250 µm or smaller. This is achieved by combining all spectra, acquired from a matrix array coating a 
single  tissue  section,  into  a  sum  spectrum.  Mass  filters  are  applied  to  the  sum  spectrum,  which 
subsequently mines data from the individual spectra in the data set, presenting the normalised intensity 
of individual mass ranges as a 2-D heat map (see Figure 3d). It is this heat map, otherwise known as an 
ion intensity map, which allows visualisation of peptide and protein distribution across a tissue section. 
It is thus possible to document changing molecular profiles as tissue composition changes, a process 
which can be likened to molecular histology [55]. Int. J. Mol. Sci. 2011, 12                       
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9. Software for Data Analysis 
Several software platforms are currently available, which generate ion intensity maps from spatially 
referenced IMS data. A selection of IMS software platforms that were available as of 2008 were listed 
in Jardin-Mathe et al. (2008) [56] along with important features. Most vendors offer IMS software 
packages for their MS instruments, including Shimadzu Biotechnology (Intensity Mapping software), 
AB-SCIEX (TissueView software), Bruker Daltonics (flexImaging software), Waters (conversion tool 
to use BioMAP) and Thermo Fisher Scientific (ImageQuest software). 
Additional freeware programs available include Novartis BioMap, data cube explorer (AMOLF, 
Amsterdam, Netherlands), fxSpectViewer (CEA, Saclay, France), Mirion (Justus Liebig University, 
Giessen, Germany) and the MALDI imaging team imaging computing system (MITICS, Lille, France) 
[56].  Of  the  mentioned  software,  only  BioMap  and  data  cube  explorer  are  readily  available  by 
download.  Data  cube  explorer,  for  example,  uses  a  universal  IMS  file  format  ―imzML‖  to  avoid 
problems with file compatibility for newly developed software. ImzML, is based on the proteomics 
standard mzML [57] and is currently being proposed as a global IMS standard because it maintains the 
spatial coordinate system of IMS data in a universally recognisable format; in this case a smaller file 
for meta data and a larger binary file for the MS data (see http://www.maldi-msi.org/ and Rö mpp et al. 
(2011) [58]). The widespread use of imzML would allow IMS researchers to directly access publicly 
available  datasets,  compare  data  sets  to  their  own,  and  compile  analysis  scripts  to  accompany 
published  data.  Both  BioMap  and  data  cube  explorer  are  available  for  download  from 
http://www.maldi-msi.org/, along with tutorials on usage. 
10. Automated Sample Preparation for Imaging Cancer Tissues 
IMS matrix deposition can be achieved using manual deposition of dry matrix powder via a sieve or 
sublimation,  nebulising  instruments  such  as  handheld  air  brushes  [55]  and  the  Bruker  Daltonics 
ImagePrep station [39], or printers such as the Labcyte Portrait [59] and Shimadzu Chemical Inkjet 
Printer (ChIP-1000) [60]. Table 5 summarises important features, advantages and disadvantages of the 
four most common matrix deposition methods. Similar to matrix choice, deposition method can also be 
bio-molecule  specific.  For  example,  dry  deposition  or  sublimation  of  matrix  leads  to  poor 
incorporation of larger molecules such as peptides and proteins into matrix crystals because there is no 
extracting solvent. As a result this type of deposition is typically employed for IMS of metabolites and 
lipids,  which  have  a  higher  ionisation  efficiency.  The  air  brush  and  ImagePrep  station  are  more 
efficient in terms of sample incorporation into the matrix crystals and are suitable for all bio-molecule 
types (optimisation of methods may be necessary). However, only experienced users should attempt air 
brush deposition of matrix, as volume, flow and subsequently reproducibility are difficult to control 
(see Table 5). Greater control is possible for nebulisation using the ImagePrep, where matrix solution 
is  gravity  fed  onto  a  porous  metal  film,  which  is  vibrated  by  current  flow  through  an  attached 
piezoelectric sheet. As a result, the matrix is vaporized (nebulised) and settles as a dense mist onto the 
tissue section. Matrix deposition in the ImagePrep is controlled by measurement of light scatter, which 
increases with greater crystal density. These nebulised preparations generate a homogeneous matrix 
field where the spatial acquisition resolution is usually limited to 20–50 µm for the homogeneous Int. J. Mol. Sci. 2011, 12                       
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matrixes (CHCA and SA, see Table 4), although higher resolution work has been reported for manual 
spray preparations [55]. A steady loss of MS sensitivity (i.e., ion count intensity) is experienced as 
resolution is increased, as a result of the smaller area and therefore smaller amount of sample being 
analysed. Importantly, the push button functionality of the ImagePrep and its standardised methods 
make it a viable candidate for clinical application. 
Printed  IMS  arrays  are,  in  effect,  whole  tissue  profiling  experiments  generated  by  repeated 
deposition of picolitre volumes of matrix in a rectangular grid (see Figure 2). Deposition of matrix in 
this manner limits users to a maximum acquisition of resolution determined by the droplet size on the 
tissue which can vary from 150-250 µm, centre to centre, depending on the quality of the preparation.  
Table  5.  Summary  of  reproducibility,  acquisition  resolution,  the  advantages  and  the 
disadvantages of four different matrix deposition methods are listed here for air brushes 
and the ImagePrep station (matrix nebulising/spray instruments) as well as the ChIP-1000 
and Labcyte Portrait (matrix printing instruments). 
 
Nebulising instruments  Printers 
Air brush  ImagePrep station  ChIP-1000  Labcyte Portrait 
Reproducibility  Poor  Good  Excellent  Excellent 
Acquisition 
resolution 
≥5 µ m  ≥20 µm  ≥150 µm  ≥150 µm 
Advantages 
Cheap  Automated  Automated  Automated 
High resolution MS 
acquisition 
High resolution MS 
acquisition 
Control over 
reagent volume 
deposited 
Control over reagent 
volume deposited 
Good for start up 
imaging MS 
laboratories 
Default methods 
available but methods 
can be modified by user 
High MS sensitivity  High MS sensitivity 
Disadvantages 
Lower 
peptide/protein 
incorporation into 
matrix 
Lower peptide/protein 
incorporation into matrix 
Expensive  Most expensive 
Requires 
experienced user 
Requires experienced 
user 
Time consuming 
preparation 
Time consuming 
preparation 
Manual preparation  Expensive 
Lower data 
acquisition 
resolution than 
nebulised 
preparations 
Lower data 
acquisition 
resolution than 
nebulised 
preparations 
 
The ChIP-1000, for example, uses a pressure manifold to maintain solution in a reservoir mounted 
on  top  of  a  55  µm  printing  nozzle.  Droplets  ranging  from  100 –200  pL  are  ejected  using  force 
generated by current flow through a piezo electric material. The principal down side to the ChIP-1000 
is the nozzle itself, which can clog with crystallised matrix. In terms of printing, DHB is the most 
stable  ChIP-1000  matrix.  Because  DHB  is  water  soluble,  and  water  is  not  as  volatile  as  organic 
solvents, printing can be performed for hours without direct supervision. However, several solid ionic Int. J. Mol. Sci. 2011, 12                       
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matrixes (e.g., CHCA with molar excess of aniline, see Table 4) have been developed that increase 
print stability by reducing the rate of CHCA and SA crystallisation [61]. The gold standard for printed 
arrays is a nozzle free system such as the Labcyte Portrait printer, which focuses sound waves at the 
surface of a matrix solution. Turbulence at the surface ejects droplets (of similar size to the ChIP-1000) 
vertically onto the tissue section which is suspended, face down, above the solution tray [59]. The high 
cost  of  this  instrument  and  methods  to  overcome  matrix  clogging  issues  on  the  ChIP-1000  have 
unfortunately prevented widespread application of the Portrait. 
As already discussed, there is a balance between sensitivity and spatial resolution. Because the 
volume  of  matrix  deposited  is  greater  for  printers  than  nebulising  instruments,  sample  extraction 
efficiency is also greater, leading to improved MS sensitivity. However, for the purposes of a grading 
approach there is typically no reason to implement the highest resolution nebulised IMS methods, with 
most studies settling for a 100–200 µm spatial resolution [39]. Moreover, deposition of printed arrays 
or singular spots onto a tumour section, whether guided by histology or independent of it, is more than 
sufficient to generate MS profiles for grading and biomarker detection  [28,30,62]. 
11. Peptide Imaging Provides Data Complementary to Protein Imaging 
Despite advances such as HFIP solvent for improved protein extraction, for the moment, IMS is 
limited to masses below 70 kDa [31], preventing ready detection of higher molecular weight proteins 
such  as  cell  surface  receptors.  Moreover,  MS  sensitivity  decreases  dramatically  as  protein  mass 
increases.  Consequently,  only  the  very  highest  abundance  high  molecular  weight  proteins  will  be 
observed. To circumvent these issues, it is possible to perform in situ proteolytic digests by deposition 
of enzymes such as trypsin. The digested tissue is coated with matrix (homogeneous layer or printed 
array)  and  MALDI-TOF  MS  acquisition  is  performed  in  the  peptide  mass  range  (0–6  kDa,  see  
Figure 1). The resulting peptide MS spectra (Figure 3c) are vastly more complex than the protein level 
(Figure 3a). However, digest methods allow (i) higher molecular weight proteins to be analysed via 
their component peptides, (ii) fragmentation of highly abundant peptides directly from tissue to gain 
sequence information [63] and (iii) direct extraction from the tissue and identification using LC-MS 
methods, which are well established in most proteomics facilities [64]. 
12. Using Histology to Guide Imaging Mass Spectrometry 
After  MS  acquisition  is  complete,  the  matrix  crystals  can  be  removed  using  ethanol  to  allow 
histological staining and assessment by a pathologist. MS compatible stains such as cresyl violet can 
also be used prior to IMS to guide analyses [47,48]. Importantly, good correlation between MS ion 
intensity  maps  and  anatomical  structures  has  been  demonstrated  previously  for  various  tissues 
including neuroendocrine [65], breast [39] and ovarian cancer (see Figure 3d) [64]. This correlation 
shows the value of IMS as a complement to histology. 
The ability to  correlate histology  and IMS data was exploited recently for investigation of the 
changing molecular profile of tumour interfaces. Upon analysis of the tumour boundaries of renal cell 
carcinoma,  the  definition  of  ―normal‖  surrounding  tissue  has  been  called  into  question,  with 
demonstration  of  potential  tumour  associated  protein  changes  appearing  well  past  the  histological 
tumour margin [66]. In a separate study on serous ovarian carcinomas, IMS was used to show that the Int. J. Mol. Sci. 2011, 12                       
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tumour interface zone contains a unique set of MS detectable masses as compared to tumour and 
surrounding normal tissue [29]. IMS can thus generate molecular data which is unique and novel to 
that provided by morphology alone. 
13. Ovarian Cancer Biomarker Discovery Using Imaging Mass Spectrometry 
In  developing  the  IMS  technology,  preliminary  IMS  biomarker  discovery  projects  for  ovarian 
cancer have been reported by the same group that presented profiling work on ovarian carcinomas  
(see Section 7). Putative biomarkers of ovarian cancer were detected using printed IMS arrays and 
subsequently  identified  using  LC-MS/MS  of  digested  cancerous  tissue  [30].  These  included  11S 
proteasome  activator  complex  Reg  Alpha  fragment  [28],  oviductin  (mucin-9)  [30]  and  
orosomucoid [30], the roles of which are described briefly here. Reg-Alpha, or PA28, is an antigen 
processing  protein,  an  increased  expression  of  which  may  allow  presentation  of  self  peptides  on 
tumour cells, and subsequently immune evasion [28,30]. Oviductin is a marker of oviductal epithelium 
and tubal differentiation marker [30,67], and finally orosomucoid is an acute phase protein previously 
evaluated  as  a  marker  of  ovarian  cancer  and  possible  immune  suppressor  through  action  on  T 
lymphocytes [30,68]. It is clear that relevant markers of disease can be identified. However, more work 
is required to determine how effectively MS profiles of such markers can distinguish the subtypes of 
ovarian cancer and how well these markers translate to cancer detection and screening. 
Figure 4. MALDI-TOF mass spectrometry profiles of ovarian carcinoma and benign tissue 
sections (a). The individual profiles of three carcinomas and three benign tumour sections 
are shown in (c), with the mass at 9744.8 m/z highlighted as the potential biomarker 11S 
proteasome  activator  complex  Reg  Alpha  fragment.  Figure  reprinted,  with  permission, 
from Lemaire et al. (2007) [28]. 
 
14. Application of Tryptic Digestion to Formalin-Fixed Paraffin Embedded Ovarian Tissues 
Frozen tissue represents the current gold standard for IMS, given that a freshly preserved tissue will 
harbor a freshly preserved proteome, which is easy to access using standard methods for both protein 
and tryptic peptide IMS (see Figure 3). However, the limited archival life of frozen tissue (maximum Int. J. Mol. Sci. 2011, 12                       
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two years for proteomics applications) has forced researchers to adopt methods for accessing peptide 
and protein mass data in formalin-fixed paraffin embedded (FFPE) tissue; the current global standard 
for long  term tissue preservation  in  medical centres and  research laboratories  worldwide  [69–71]. 
However, formalin fixation induces cross-linking between multiple amino acid side chains, creating a 
linked protein network [72]. To access these tissues by MS, antigen retrieval (AR) [62,64] and/or in 
situ tryptic digestion [73,74] are required. While AR is not completely understood, its most likely 
effects are to partially hydrolyse cross-links and denature linked proteins. Typically, this is insufficient 
for subsequent MS acquisition of the same quality as frozen tissue, because the cross-linking is not 
reversed completely. Thus, AR is usually followed by tryptic digestion [62]. 
Figure 5. MALDI-TOF IMS of formalin-fixed paraffin-embedded (FFPE, top row) and 
frozen (bottom row) ovarian carcinoma. FFPE sections were treated with antigen retrieval. 
Frozen sections were washed using a previously described protocol. Both sections were 
digested with trypsin and coated with CHCA matrix using an ImagePrep station. Figure 
reprinted, with permission, from Gustafsson et al. 2010 [64]. Scale bars = 2 mm. 
 
Several publications have so far demonstrated successful application of AR methods for IMS on 
various  tissues  [62,74,75],  including  FFPE  ovarian  cancer  [64,73].  A  2007  study  applying  tryptic 
digestion alone to de-paraffinised and rehydrated sections of ovarian cancer showed that many high 
abundance proteins could be identified directly from tissue [73]. However, this study was a proof of 
principle  application  and  as  such  did  not  demonstrate  disease  specific  distribution  of  peptides 
generated from the tissue sections. Our own group has successfully applied citric acid antigen retrieval 
to ovarian cancer for tryptic peptide IMS (see Figure 5). Peptides were also extracted from in situ 
proteolytic digests and identified using liquid phase peptide separation and MS. Using this method it 
was possible to assign tentative identities to 48 individual peptides [64]. Because of the ability to 
rapidly  extract  and  identify  peptides  directly  from  tissue  using  ―classical‖  fractionation-based 
proteomics, the translation from peptide IMS data to peptide identification and subsequent in situ 
validation by IHC becomes less labour intensive. Furthermore, the large existing archives of FFPE 
ovarian  tissue  will  allow  any  acquired  peptide  IMS  data  to  be  matched  to  patient  history  and  
clinical outcome. Int. J. Mol. Sci. 2011, 12                       
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15. Conclusions and Future Prospects 
The successful application of MS profiling and IMS for tissue classification and grading has been 
demonstrated for different types of cancer. In the case of ovarian cancer, preliminary studies have 
isolated and identified potential tissue specific peptide and proteins masses using IMS. The current aim 
is continued application of in situ MS methods to demonstrate acquisition of ovarian cancer grade 
and/or  subtype  specific  protein/peptide  profiles  from  both  frozen  and  archived  FFPE  tissues. 
Importantly, from further investigation, IMS derived markers could be used to track molecular changes 
across ovarian tumours as well as their interfaces with normal tissue to determine the importance of 
subsequent  protein  and  peptide  masses  as  tissue  markers.  Following  selection  of  these  specific 
markers,  identification,  as  already  demonstrated  in  several  publications,  can  be  achieved  using 
classical proteomics at either the protein or peptide level (fractionation/identification methods such as 
LC-MS). Subsequent validation of these masses using IHC will ultimately indicate the suitability of 
masses for further development as diagnostic markers for ovarian cancer sub-type or grade and for 
validation in large patient cohorts as biomarkers. 
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